Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
Stephanie Fortier, PhD
Advertisement
Articles by Stephanie Fortier, PhD
Advertisement
Latest Updated Articles
Oncologists’ Perceptions and Utilization of US Therapeutic Oncology BiosimilarsPublished: December 8th 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
3
Value-Based Care Interventions and Management of CKD Progression
4
Defining the Role of Rilzabrutinib in ITP Management
5
